HomeInsightsResults

Marksans Pharma Ltd Quarterly Result

Marksans Pharma Ltd Quarterly Result

stocks purchased

₹ 3.2 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

104.3 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Marksans Pharma Ltd

NSE: MARKSANS

Net Profit

₹ 97.76

Last updated on: Nov 23, 2024

Key Highlights

  • The revenue of Marksans Pharma Ltd for the Sep '24 is ₹ 652.98 crore as compare to the Jun '24 revenue of ₹ 605.57 crore. This represent the growth of 7.828983%.
  • The ebitda of Marksans Pharma Ltd for the Sep '24 is ₹ 146.74 crore as compare to the Jun '24 ebitda of ₹ 143.39 crore. This represent the growth of 2.33629%.
  • The net profit of Marksans Pharma Ltd for the Sep '24 is ₹ 97.76 crore as compare to the Jun '24 net profit of ₹ 89.07 crore. This represent the growth of 9.756374%.

Results Analysis

Market Price of Marksans Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Marksans Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024308.55
21 Nov 2024309
19 Nov 2024305.85
18 Nov 2024309.3
14 Nov 2024307.35
13 Nov 2024305.55
12 Nov 2024300.35
11 Nov 2024289
08 Nov 2024298.6
07 Nov 2024301.35

Historical Revenue of Marksans Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Marksans Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Marksans Pharma Ltd

No data available

* All values are in crore

Marksans Pharma Ltd News Hub

News

Marksans Pharma receives USFDA approval for Loratadine Tablets

Marksans Pharma announced the final approval of the Company's Abbreviated New Drug Applica...

Read more

22 Nov 202412:47

News

Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA

The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and u...

Read more

22 Nov 202413:23

News

Marksans Pharma gains after Q2 PAT rises 16% YoY to Rs 97 cr

The firm stated that growth was witnessed across all key markets, led by US and followed b...

Read more

12 Nov 202413:22

News

Marksans Pharma to declare Quarterly Result

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 Novembe...

Read more

23 Oct 202417:41

News

Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules

Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

21 Aug 202420:00

News

Marksans Pharma's Verna unit successfully completes USFDA inspection

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR...

Read more

20 Aug 202414:37

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Marksans Pharma Ltd Quarterly Result

What is the EPS of Marksans Pharma Ltd stock?

The Earnings Per Share (EPS) of Marksans Pharma Ltd is 7.66. An EPS is the amount of net income attributed to each share of a common stock.

How is Marksans Pharma Ltd EPS calculated?

The EPS of Marksans Pharma Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Marksans Pharma Ltd report its EPS?

Marksans Pharma Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Marksans Pharma Ltd EPS?

Factors that influence the EPS of Marksans Pharma Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Marksans Pharma Ltd EPS growth indicate future performance?

Yes, consistent growth in Marksans Pharma Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*